Brenntag acquires mcePharma to expand GMP capabilities in biopharma services

Ella Day | June 5, 2025 | News story | Manufacturing and Production, Mergers and Acquisitions Brenntag Specialities, Corporate, acquisition, continuous monitoring platform (CMP), mcePharma 

Brenntag Specialties has acquired Czech-based mcePharma, strengthening its position in the pharma and biopharma industries through expanded continuous monitoring platform (CMP) capabilities and a more strategic presence in central Europe.

The acquisition will enable Brenntag to develop a central hub for good manufacturing practice (GMP) value-added services across Europe, the Middle East and Africa (EMEA), supporting increased demand for customised solutions in the biopharma market. Existing facilities at mcePharma include advanced GMP infrastructure and over-the-counter product development capacity. All will be integrated into Brenntag’s broader life sciences service offering.

Also, the company announced additional investment at the site to scale GMP blending, down-packing and biobuffer production. These are intended to improve operational efficiency and meet growing needs for high-quality, compliant formulation and distribution services.

Advertisement

“This is a powerful enhancement to our portfolio that reinforces our commitment to quality, speed and customer-centric solutions,” said Joakim Rehné, president of pharma EMEA at Brenntag.

Ivan Mikes, administration board member at mcePharma, added: “Our team will get the chance to leverage their expertise and serve the entire EMEA region together with Brenntag.”

Gust Desmedt, global president pharma at Brenntag, commented: “This acquisition represents a key milestone in our strategic initiatives to further expand our biopharma services.”

Ella Day

5/6/25

The Pharmafile Brief

This article featured in: July 2025 – The Pharmafile Brief

Related Content

handshake_2

Curium Pharma announces acquisition of Monrol

Curium Pharma, a nuclear medicine company, has acquired Eczacıbaşı-Monrol Nuclear Products (Monrol), a nuclear medicine …

Enosium Life Science acquires RWEality

Enosium Life Science, which specialises in life sciences, has acquired RWEality, a consultancy focused on …

CANDOR Bioscience acquired by Medix Biochemica

CANDOR Biosciences, a supplier in immunoassay solutions, has been acquired by Medix Biochemica, a supplier …

The Gateway to Local Adoption Series

Latest content